Onconetix

Biotechnology
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

$2.4M

Market Cap • 7/4/2025

2018

(7 years)

Founded

2022

(3 years ago)

IPO

NASDAQ

Listing Exchange

Flag of US

Cincinnati

Headquarters • Ohio